Stacking MOTS-c & Tesamorelin with Retatrutide
This is a five-compound recomposition stack built around a low dose of retatrutide, MOTS-c, and Tesamorelin. The goal is not maximum scale loss but recomposition: strip fat while holding onto muscle.
Retatrutide does the heavy lifting on fat. Beyond appetite control, its glucagon arm actively mobilizes stored fat from the liver, which is what sets it apart from semaglutide and tirzepatide. From there the stack makes sure that mobilized fat gets burned: L-Carnitine is added as support to move fatty acids into the mitochondria. MOTS-c restores their ability to run on fat, and NAD+ supplies the cofactor combustion spends. Tesamorelin is the counterweight — a growth-hormone pulse that defends lean mass so the deficit costs fat, not muscle.
The five compounds sit at different evidence levels, and the differences change how much weight each layer carries. Retatrutide is in Phase 3 with dose-response data. Tesamorelin is FDA-approved, for HIV-associated lipodystrophy rather than as an anabolic agent, and its lean-mass effect comes from that indication’s trials. Native MOTS-c has never been given to a person in a completed trial — the registered Phase 1a/1b program studied CB4211, an engineered analog, and posted no results. L-Carnitine and NAD+ are supporting compounds with mechanism behind them and no recomposition endpoint.
Evidence Status
| Evidence layer | What supports this protocol |
|---|---|
| Direct human evidence | Retatrutide and tesamorelin each have human trial data for separate indications. The complete stack has not been tested in humans. |
| Mechanistic inference | Appetite control, GH-axis signaling, fatty-acid transport, mitochondrial adaptation, and NAD+-dependent oxidation form the rationale for the combined design. |
| Field observation | The low-dose retatrutide range, sequencing, and multi-compound cadence come from published field protocols and reported tolerability. |
| Untested combination | Retatrutide + Tesamorelin + MOTS-c with L-Carnitine and NAD+ is an untested combination, not a measured recomposition endpoint. |
| The Dual-Axis Recomp Stack At a Glance | |
|---|---|
| Who it’s for | Experienced users training 4+ days/week, holding fat loss against performance |
| Duration | 12 weeks |
| Key components | Retatrutide (0.3-2 mg/wk), NAD+, L-Carnitine, MOTS-c, Tesamorelin |
| Results timeline | Recomposition surfaces by weeks 4-8 when training, protein, and sleep hold |
| Difficulty | Advanced |
This is an advanced-level protocol. It assumes consistent training (4+ days per week), adequate protein intake, and comfort with multi-compound stacks. For a simpler starting point, see the Retatrutide + NAD+ support protocol.
The Problem with GLP-1 Monotherapy
GLP-1 agonists work. The appetite suppression is real and the deficit follows, and the outcomes still come out wrong.
People can get lighter but weaker. Thinner but exhausted. The scale moves, but energy does not follow. In the matched non-T2D DXA anchors, semaglutide’s STEP-1 lean fraction was roughly 38-39% of fat-plus-lean loss, while tirzepatide’s SURMOUNT-1 DXA lean fraction was about 25%.⁸ That does not mean muscle loss is inevitable. It means protein, training, dose discipline, and repair support decide whether the deficit looks like fat loss or mixed tissue loss.
GLP-1 drugs create deficits by suppressing appetite. A deficit is pressure without direction. Without enough training signal, protein, recovery, and oxidation capacity, the weight lost can include too much lean tissue.
Weight loss requires two axes working together:
- Central axis — appetite, intake behavior, the decision to eat. GLP-1s address this effectively.
- Peripheral axis — oxidation machinery, mitochondrial capacity, the ability to burn what’s been mobilized. GLP-1s do not automatically solve this axis.
This is why GLP-1 monotherapy can produce weight loss without high-quality recomposition.
Why Retatrutide Is Different
Retatrutide is a full agonist at all three receptors, but with different functional potencies: GIPR is substantially more potent than native GIP, while GLP-1R and GCGR are less potent than their native ligands.⁹ The third receptor — glucagon — separates retatrutide from its predecessors.
Glucagon receptor activation actively mobilizes stored fat. The liver is signaled to oxidize its existing triglyceride stores rather than relying on a caloric deficit to drain them passively. In the liver substudy, β-hydroxybutyrate rose +93% at 4 mg and +181% at 12 mg. The receptor pharmacology supplies the GCGR attribution; the human biomarker shows that the predicted hepatic-fat-oxidation signal appears.⁶ ⁹
But the glucagon arm is dose-gated. Its peripheral effects - heart-rate elevation, sustained lipolysis, chills, and the broader tissue-weakening pressure that can put lean mass at risk - rise as dose and titration speed rise. At 0.3-2 mg, the hepatic signal can be useful, but lean and sensitive users can still feel heart-rate or autonomic effects early.
There is a second edge to the glucagon arm, and it is the reason this protocol exists. The same liver signal that burns fat also tells the liver to pull amino acids out of the blood and use them for fuel and glucose. Amino acids are the building blocks of protein, including muscle, and the leftover nitrogen leaves the body as urea. Reta shows this directly: at 12 mg, the blood level of alanine (the amino acid muscle ships to the liver) falls by about half⁷. That drop reads as the glucagon arm working rather than as a muscle-loss measurement by itself. The amino acids the liver burns still have to come from somewhere, and in a deficit without enough dietary protein, some come from muscle. The pull grows with dose. That is the tissue-weakening pressure the protein, training, and Tesamorelin layers are built to offset.
At high doses (8-12 mg), retatrutide behaves more like a maximum weight-loss drug: peak weight loss, higher glucagon-class side-effect burden, and more support burden. The Phase 2 arms show where that trade turns — 8 mg captured 22.8% weight loss against 24.2% at 12 mg. The top of the range bought 1.4 points for a materially larger side-effect load.¹ This protocol uses retatrutide differently: as a low-dose metabolic controller, at 0.3-2 mg weekly. Above that range the protocol stops being a recomposition plan and becomes a weight-loss plan with a support stack attached.
The Fat-Burning Chain
Fat burning is a chain, and each link matters:
- Retatrutide → releases fat from storage (mobilization)
- L-Carnitine → transports fat into mitochondria (logistics)
- MOTS-c → restores the machinery’s ability to burn fat (the capacity)
- NAD+ → provides capacity to complete combustion (execution)
If one link is missing, the stack becomes less efficient and harder to tolerate.
Retatrutide Mobilizes Fat
The glucagon arm pushes the liver toward active fat oxidation — Sanyal 2024 measured β-hydroxybutyrate elevation of +93% at 4 mg and +181% at 12 mg, a marker of hepatic fatty-acid oxidation.⁶ Fat leaving storage is not the same as fat being fully burned. The downstream chain (transport, mitochondrial preference, NAD+ cofactor capacity) determines whether mobilized fat becomes usable energy. See Retatrutide deep-dive.
L-Carnitine Transports Fat
Long-chain fatty acids cannot cross the inner mitochondrial membrane on their own. They require the carnitine shuttle.⁴ Without adequate carnitine, fatty acids can remain outside the mitochondria instead of being moved into the oxidation pathway. Read about L-Carnitine
MOTS-c Restores Flexibility
Fat inside the mitochondria still has to be oxidized. Metabolic flexibility is the capacity to switch between glucose and fat as fuel, and it degrades with age and metabolic dysfunction.
MOTS-c is a mitochondrial-derived peptide the body releases during exercise; given as a peptide, it activates the same energy sensor exercise does (AMPK³). AMPK does two things at once here: it improves glucose uptake and insulin sensitivity in muscle, and it phosphorylates ACC, which lifts the brake on the shuttle that carries fat into the mitochondria (CPT-1³) and raises fat oxidation. The discovery work measured both arms directly, higher carnitine shuttles and β-oxidation intermediates alongside faster glucose clearance. MOTS-c upgrades the machinery’s ability to run on either fuel rather than switching it from one to the other. In a system that has defaulted to glucose, that surfaces as regained fat-burning: in aged mice stuck on carbohydrate, MOTS-c brought fuel use back toward fat, and treated cells could survive on lipids without glucose.
The limit that matters is magnitude in a person like this reader. Every efficacy result is in cells and mice, injected at doses far above anything a person would use; in humans MOTS-c has been measured rising with exercise but has never been given as a treatment. The direction is grounded in mechanism and in human endogenous physiology; the size of the effect in a person is not established. Learn more about MOTS-c.
NAD+ Completes Combustion
Once the machinery is set up to oxidize fat, it needs cofactor capacity to complete beta-oxidation. NAD+ is the electron carrier that fat oxidation spends every cycle.⁵ Without enough NAD+ availability or recycling capacity, the chain can bottleneck: fat is mobilized, transported, and queued for burning, but the user feels underpowered.
The subjective experience is fatigue, brain fog, and the sense of being "wired but underpowered."
Understand why NAD+ is a critical support layer for GLP-1s.
The Anabolic Layer: Tesamorelin
The first four layers create a deficit and route it toward fat. None of them actively protect lean tissue. Under strong catabolic pressure, the body can still pull from lean mass.
Tesamorelin adds the anabolic counterweight. It’s a GHRH analog that restores pulsatile growth hormone secretion rather than supplying exogenous GH. The distinction matters: tesamorelin preserves the body’s natural rhythm rather than flattening it.
In clinical trials, tesamorelin produces selective effects:²
- Visceral adipose tissue decreases
- Lean mass is preserved or modestly increased
- Hepatic fat fraction drops
The visceral fat reduction creates a feedback loop. Visceral fat secretes inflammatory cytokines, worsens insulin resistance, and impairs fuel-routing. As visceral fat decreases, insulin sensitivity improves, and the fat-as-fuel bias becomes easier to maintain.
Circadian alignment matters: GH secretion is naturally nocturnal. Tesamorelin amplifies this pattern, supporting a clean division — daytime for AMPK-dominant oxidation, nighttime for mTOR-dominant repair. See Tesamorelin deep dive.
Alternatives and Add-Ons
Ipamorelin is the modern GHRP choice when tesamorelin is unavailable or when a GH-pulse amplifier is needed — see the GH secretagogue comparison. It drives a short ghrelin-receptor GH pulse with less cortisol, ACTH, prolactin, appetite, and histamine noise than older GHRPs. It is usually dosed 100-300 mcg SubQ before bed, ideally at least 2 hours after food and 60-90 minutes before sleep. It can also be combined with tesamorelin when a stronger GH pulse is appropriate.
AOD-9604 is the lipolytic fragment of growth hormone (amino acids 176-191) — it signals fat cells to mobilize stored energy without raising IGF-1 or affecting insulin sensitivity.
Its safety file is stronger than its efficacy file, and both are worth stating plainly. Across six company-sponsored human trials, AOD-9604 moved neither IGF-1, nor glucose tolerance, nor anti-drug antibodies in a concerning direction. The obesity program was nonetheless terminated in February 2007 after the Phase IIb OPTIONS trial (n=536, 24 weeks) missed its primary endpoint at both 12 and 24 weeks. The one positive arm is the earlier 2004 Phase IIb (n=300, 12 weeks), where 1 mg oral daily produced 2.6 kg weight loss against 0.8 kg on placebo.¹¹
Two gaps travel with using it here. That positive result was oral at 1 mg, while this protocol and community practice use 250-500 mcg subcutaneously — a different route and roughly a quarter of the dose, with no human subcutaneous efficacy or PK data behind it. And chronic exposure beyond 24 weeks is uncharacterized at any dose or route. AOD-9604's safety record is the strong part of its file; at this route and dose its effect size is unmeasured. Dosing where it is used: 300 mcg SubQ fasted AM.
Retatrutide Recomposition Protocol
| Compound | Dose | Frequency | Route | Timing |
|---|---|---|---|---|
| Retatrutide | 0.3-2 mg total weekly | Weekly or q3d split | SubQ | Same schedule each week |
| NAD+ | 50-200 mg | 2-3×/week | IM | Morning or mid-day |
| L-Carnitine | 200-500 mg | 5-7×/week | IM | Fasted, or pre-training |
| MOTS-c | 5-10 mg | 2-3×/week | SubQ | Fasted, pre-training |
| Tesamorelin | 1-2 mg | Nightly | SubQ | Before sleep, 2+ hrs after last meal |
Retatrutide holds each step for 4+ weeks, without climbing through active side effects.¹⁰ The q3d option is a split of the weekly target, not the full weekly amount every three days: each injection is three-sevenths of the total weekly dose. NAD+ ramps slowly; diluting or splitting eases the local burn. L-Carnitine runs toward 1000 mg briefly as a loading option, with 200-500 mg the normal working range. IGF-1 reads at weeks 4 and 12 on a Tesamorelin arm.
Note: For NAD+, intramuscular injections are the preferred route. SubQ is feasible at 50-100 mg per dose, split into injections of 50 mg or less; above 100 mg use IM.
The reconstitution calculator gives exact injection volumes for each compound. Separate syringes, one per compound — this stack is an architecture, not a cocktail vial.
Weekly Schedule (Example)
| Compound | Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|---|
| Retatrutide | 1 mg | — | — | — | — | — | — |
| NAD+ | 100 mg | — | 100 mg | — | 100 mg | — | — |
| L-Carnitine | 500 mg | 500 mg | 500 mg | — | 500 mg | 500 mg | — |
| MOTS-c | 5 mg | — | 5 mg | — | 5 mg | — | — |
| Tesamorelin | 1-2 mg | 1-2 mg | 1-2 mg | 1-2 mg | 1-2 mg | 1-2 mg | 1-2 mg |
Note: MOTS-c is dosed 2-3× weekly by field convention, not because a measured duration of action supports that spacing. The nuclear signal is brief and self-limiting — back to baseline within 24 hours — while the adaptations accrue over weeks, which makes the peptide a repeated pulse rather than a level to maintain. Native human pharmacokinetics after injection are unmeasured, and no study has compared dosing frequencies in any species. No study has compared frequencies, which leaves the ceiling unmeasured rather than established.
| Phase | Duration | Protocol |
|---|---|---|
| On | 4-6 weeks | 5-10 mg, 2-3×/week |
| Off | 2-4 weeks | Continue other compounds |
Lifestyle Foundation
| Component | Target |
|---|---|
| Protein | ≥1.2 g/kg; up to 2.2 g/kg for training/aggressive deficits |
| Carbohydrates | Increased intake of fruit before training |
| Training | 4-5 days/week; resistance + Zone 2 cardio |
| Cardio timing | Fasted morning after L-Carnitine |
| Sleep | 7-9 hours; Tesamorelin timing requires consistent bedtime |
| Hydration | 3-4 liters daily |
Timeline: What to Expect
Weeks 1-4
- GH adaptation — Sleep deepens within first week
- Fat loss — Appetite, waist, and training tolerance start to show whether the dose is adequate
- Recovery — Training recovery noticeably faster
- Water — GH-related retention may occur; resolves by week 3-4
- Muscle — Fullness maintained despite deficit
Weeks 5-8
- Recomposition — Waist drops while strength and limb fullness hold
- Performance — Strength is maintained or improves; endurance may rise
- Visceral fat — Belt notches move; trunk tightens
- Energy — Often steadier than expected despite lower intake
Weeks 9-12
- Definition — Stubborn areas may begin to move if training, sleep, and intake are consistent
- Cumulative — Fat loss and lean-mass preservation depend on training, protein, sleep, and dose discipline
- Metabolic markers — Glucose, triglycerides, HDL, and liver enzymes may improve
- State — The protocol should feel tolerable, not like a constant fight against side effects
What the timeline is built from
The retatrutide half comes from Phase 2 and Phase 3 dose-response data, at a different population and a higher-dose frame than this protocol uses. The tesamorelin half comes from its own trials. The sequencing, the low-dose range, and the week-by-week rhythm come from field protocols rather than a trial of this stack. Training, protein, sleep, and dose discipline move these outcomes more than any compound in the table does — a reader running the stack without them gets the side-effect profile and not the recomposition.
When Progress Stalls
| Step | Lever |
|---|---|
| 1 | Protein intake, carbohydrate floor, steps, and sleep quality — the foundation first |
| 2 | Quiet retatrutide side effects before any dose change |
| 3 | L-Carnitine toward 500-1000 mg/day where fatty-acid transport is the bottleneck |
| 4 | NAD+ toward 200 mg per dose, or cleaner dilution / route where irritation limits use |
| 5 | One added Zone 2 cardio session |
| 6 | Stubborn subcutaneous fat: AOD-9604 300 mcg fasted AM as the adjunct |
Managing Side Effects
| GH Related (Tesamorelin). | Response |
|---|---|
| Water retention (weeks 1-3) | Transient; adequate potassium |
| Joint stiffness / hand paresthesia | Eases with movement; a dose drop where it persists |
| Blood glucose elevation | Worth monitoring in diabetes; GH can transiently raise fasting glucose |
| Retatrutide | Response |
|---|---|
| Nausea/early satiety | Smaller protein-first meals; a held dose |
| Constipation | Fiber + fluids → magnesium citrate |
| Resting HR increase | A held dose; morning resting HR tracked |
| Chills or skin sensitivity | A held or lowered step, not a titration through it |
| MOTS-c / L-Carnitine | Response |
|---|---|
| Early fatigue (MOTS-c) | Usually resolves; food timing, sleep, and electrolytes |
| Injection site soreness | Rotated sites; a slow push; split larger NAD+ SubQ doses |
Monitoring
| Timepoint | What to Track |
|---|---|
| Baseline | CBC, CMP, lipids, fasting glucose/insulin, HbA1c, thyroid, IGF-1, resting HR/BP |
| Week 4 | IGF-1 (target physiologic elevation, not supraphysiologic), fasting glucose, resting HR |
| Monthly | IGF-1 while on Tesamorelin |
| Week 12 | Full panel; glucose, TG, HDL, IGF-1, liver enzymes, thyroid if fatigue/cold intolerance appears |
IGF-1 guidance: Physiologic elevation is the target. IGF-1 above 350-400 ng/mL is the threshold where the Tesamorelin dose comes down.
Post-Protocol Approaches
Maintenance:
- Retatrutide at the lowest effective dose, often 0.3-2 mg/week for recomp users
- Tesamorelin at 1 mg nightly for sleep and connective-tissue support
- NAD+ at 100-250 mg total weekly
- L-Carnitine pre-training as needed
Lean-gain phase:
- Retatrutide at the minimum effective dose
- Tesamorelin held
- A slight caloric surplus
- NAD+ and L-Carnitine continued
- The aim: slow, clean accrual of lean mass
Contraindications
- Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- Active malignancy (GH/IGF-1 axis; MOTS-c)
- Proliferative diabetic retinopathy
- Pregnancy or breastfeeding
- Uncontrolled diabetes (requires close monitoring)
- Pre-existing atrial fibrillation, structural heart disease, or sustained unexplained tachycardia without clinician oversight
FAQ
Why use low-dose retatrutide instead of full dose?
Full-dose retatrutide (8-12 mg) pushes deeper into the side-effect zone: a higher glucagon-driven heart-rate signal, more GLP-1-driven skin sensitivity (dysesthesia), stronger fat mobilization, and more tissue-weakening pressure if nutrition and training are not controlled. Chills rise in field reports but are class-shared rather than cleanly assigned to GCGR. Low-dose retatrutide keeps the GIP-forward signal active while leaving room for training, protein intake, and the lean-preservation layer to do their work. The recomp window depends on that distinction.
How does omitting the Tesamorelin layer change the protocol?
Dropping it shifts the protocol toward weight loss and away from recomposition. Tesamorelin supplies the nighttime growth-hormone signal that supports lean tissue, connective tissue, sleep-linked recovery, and visceral-fat targeting during a deficit.
Which markers are used to evaluate whether the protocol is working?
Waist circumference and strength performance read the signal more cleanly than scale weight alone. Recomposition often shows as stable or dropping weight with maintained or increased strength and a smaller waist.
What happens after 12 weeks?
Two paths open: maintenance at lower doses, or a lean-gain phase — retatrutide at 1-2 mg/week, Tesamorelin held, a slight caloric surplus. The metabolic improvements persist where the habits hold.
What does MOTS-c do in this protocol?
MOTS-c pushes cells toward the same adaptation pattern triggered by endurance training: better mitochondrial capacity and a renewed ability to use fat as fuel (AMPK signaling³). In this stack, retatrutide mobilizes fat and L-Carnitine transports it into mitochondria; MOTS-c helps the machinery use that fuel instead of defaulting back toward glucose.
MOTS-c is dosed 2-3 times per week as a field convention. The schedule recurs across published protocols and fits a signal that pulses rather than one held at a level. No measured duration of action supports the specific spacing. The protocol cycles it 4-6 weeks on, 2-4 weeks off, while other compounds continue.
Why isn’t oral L-Carnitine part of this stack?
Long-chain fatty acids cannot cross the inner mitochondrial membrane on their own — they require the carnitine shuttle system to get inside the furnace. When retatrutide’s glucagon arm mobilizes fat from storage, that fat enters the bloodstream but is not yet being burned. Without adequate carnitine, fatty acids accumulate outside the mitochondria, unavailable for oxidation.
This protocol uses injectable L-Carnitine rather than oral because intramuscular delivery bypasses the gut absorption limits that make oral carnitine less reliable. The working range is usually 200-500 mg IM, fasted or pre-training; 1000 mg daily is a short loading option, not the default.
Why does NAD+ matter during aggressive fat loss?
NAD+ is the redox cofactor beta-oxidation spends while breaking fatty acids down inside mitochondria. When the rest of this stack mobilizes, transports, and signals fat for burning, NAD+ availability becomes load-bearing. If the pool is low or demand outruns recycling, the subjective pattern is fatigue, brain fog, and feeling "wired but underpowered."
Aggressive deficits also increase NAD+ demand. This protocol uses 50-200 mg IM 2-3 times per week as the default. SubQ runs 50-100 mg per dose, split into injections of 50 mg or less, and is often better tolerated; above 100 mg use IM. During maintenance, NAD+ usually drops to 100-150 mg weekly or 2 times per week depending on fatigue, training load, and oral precursor use.
Related Topics
- Retatrutide Guide — mechanism, trials, and safety data
- Retatrutide Dosing Calculator — reconstitution math for 10/12/24mg vials
- Retatrutide vs. Tirzepatide — head-to-head mechanism and weight-loss differential
- Retatrutide + NAD+ support protocol — simpler starting point
- GLP-1 Hub — broader GLP-1 family coverage
- GLP-1 Compounds Tool — interactive comparison with trial data on weight loss and composition
- Tesamorelin Guide — the anabolic layer explained
- AOD-9604 Guide — optional lipolytic support for stubborn areas
- NAD+ Guide — cofactor support for fat oxidation
- MOTS-c Guide — mitochondrial programming peptide
- MITT-Stack White Paper — mitochondrial peptide deep-dive
- GLP-1 Muscle Preservation — body composition strategies
- Semaglutide Guide — The established GLP-1 benchmark for comparison
- Tirzepatide Guide — Dual-agonist — intermediate between semaglutide and retatrutide
- Peptide Reconstitution Guide — How to prepare each vial in the protocol
References
¹ Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023. DOI: 10.1056/NEJMoa2301972
² Stanley TL, et al. Effects of Tesamorelin on Non-Alcoholic Fatty Liver Disease. Lancet HIV 2019. DOI: 10.1016/S2352-3018(19)30338-8
³ Lee C, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis. Cell Metabolism 2015. DOI: 10.1016/j.cmet.2015.02.009 — the discovery paper; AMPK activation via the folate one-carbon cycle. The first direct molecular target was later identified as CK2α (binding affinity about 1 nM), which MOTS-c activates in skeletal muscle and suppresses in fat: Kumagai H, et al. MOTS-c Modulates Skeletal Muscle Function by Directly Binding and Activating CK2. iScience 2024. DOI: 10.1016/j.isci.2024.111212
⁴ Stephens FB, et al. Skeletal Muscle Carnitine Loading Increases Energy Expenditure. Journal of Physiology 2013. DOI: 10.1113/jphysiol.2013.255364
⁵ Yoshino J, et al. NAD+ Intermediates: The Biology and Therapeutic Potential. Cell Metabolism 2021. DOI: 10.1016/j.cmet.2020.11.007
⁶ Sanyal AJ, et al. Retatrutide for metabolic dysfunction-associated steatotic liver disease. Nature Medicine 2024. β-hydroxybutyrate rose +93% at 4 mg and +181% at 12 mg, a biomarker of hepatic fatty-acid oxidation. DOI: 10.1038/s41591-024-03018-2
⁷ Pearson MJ, Willency JA, Lin Y, et al. Retatrutide and Lipid and Metabolite Profiles in Participants With Obesity With or Without Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism. 2026. 10.1210/clinem/dgag201. Circulating alanine fell up to −53.3% at 12 mg alongside urea-cycle amino-acid changes—the fingerprint of GCGR-driven hepatic amino-acid uptake and ureagenesis. Read as GCGR-arm engagement, not a direct muscle-loss measurement.
⁸ Semaglutide and tirzepatide DXA anchors — Wilding JPH, et al. STEP 1 exploratory body-composition analysis: semaglutide 2.4 mg in non-diabetic obesity, approximately 38-39% lean fraction of fat-plus-lean loss. N Engl J Med. 2021. 10.1056/NEJMoa2032183. Look M, et al. SURMOUNT-1 DXA substudy: tirzepatide in non-diabetic obesity, approximately 25% lean fraction. Diabetes Obes Metab. 2025;27:2720. 10.1111/dom.16275.
⁹ Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34:1234-1247. Figure 1 and Table S2 report full cAMP agonism with receptor-specific potency differences. 10.1016/j.cmet.2022.07.013.
¹¹ AOD-9604 human program — Metabolic Pharmaceuticals. Phase IIb 2004 (n=300, 12 wk): 1 mg oral daily produced 2.6 kg weight loss vs 0.8 kg placebo, statistically significant and well tolerated; lower oral doses produced smaller effects. Phase IIb OPTIONS 2006-07 (n=536, 24 wk): failed primary weight-loss endpoint vs a placebo arm also on a strict diet-and-exercise regimen, at both 12 and 24 weeks; obesity development terminated February 21, 2007. Whether that failure reflects absent efficacy or a placebo control that already produced weight loss is unresolved. Across six company-sponsored trials, IGF-1, glucose tolerance, and anti-drug antibodies were unaffected — safety signals, not efficacy signals. No human subcutaneous efficacy or PK data exists at any dose; no chronic data beyond 24 weeks. WADA lists AOD-9604 under S2.2.3 (prohibited at all times) as a growth-hormone fragment. Safety background: Stier H, et al. J Endocrinol Metab 2013.
¹⁰ Nauck MA, Punov V, Kang YM, Lim S. Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting. Diabetes, Obesity and Metabolism. 2026;28:4232-4242. 10.1111/dom.70613. Tolerance tracked escalation duration and step count; within tirzepatide, full escalation shifted nausea and vomiting ED50 by about fivefold. This carries the protocol’s slow-titration logic.
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.